First generic versions of Depakote okayed in US
This article was originally published in Scrip
Executive Summary
The US FDAhas cleared for marketing the first generic competitors toAbbott Laboratories' delayed-release divalproex sodium tablets, Depakote, for the treatment of seizures, bipolar disorder and migraine headaches. The product is Abbott’s number two product, and all Depakote forms had global sales last year of $1.6 billion.